Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate at the following events in November:

BIO-Europe (November 4-6, 2024; Virtual: November 12-13, 2024)
Format: In-person/Virtual
Location: Stockholm, Sweden
Lisata representative: Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata

Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on BIO-Europe and how to register, please click here or contact EBDcustomerservice@ebdgroup.com.

PEGS Europe Summit (November 5-7, 2024)
Format: In-person
Location: Barcelona, Spain
Presentation Date: Tuesday, November 5, 2024
Presentation Time: 3:20 p.m. CEST
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata

For more information on PEGS Europe and how to register, please click here.

LSX Inv€$tival showcase 2024 (November 18, 2024)
Format: In-person
Location: Tobacco Dock, UK
Presentation Date: Monday, November 18, 2024
Presentation Time: 1:00 p.m. GMT
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata

For more information on the LD Micro Main Event and how to register, please click here or contact steph@lsxleaders.com.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s internalizing RGD, or Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.

Contact:

Investors:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com

Staff

Recent Posts

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

16 minutes ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

16 minutes ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

17 minutes ago

United Imaging Announces the First of Several New U.S. Product Launches For RSNA

The first uMI Panvivo in the world lands at the growing Pueblo Medical Imaging in…

17 minutes ago

Nearly Half of U.S. Workers Say They Won’t Deplete Allotted Vacation By Year End

85% Percent of Workers Say It Would Be Beneficial for Employers to Mandate Taking Vacation…

17 minutes ago